Medium Chain Acyl CoA Dehydrogenase Deficiency (ICD-10-CM Code: E71.311)

Name of the Condition

• Medium chain acyl CoA dehydrogenase deficiency.

Summary

Medium chain acyl CoA dehydrogenase deficiency is an inherited metabolic disorder that impairs the body's ability to break down medium-chain fatty acids for energy. This can lead to the accumulation of toxic byproducts, particularly during fasting or illness, and may cause symptoms affecting the liver, muscles, or nervous system. The condition disrupts normal metabolic pathways, potentially resulting in energy deficits or organ damage if untreated.

Causes

These disorders are caused by genetic mutations that affect enzymes or transport proteins involved in fatty-acid oxidation. Most are inherited in an autosomal recessive pattern, meaning both parents must carry a mutated gene for a child to be affected. The specific genetic defect determines the severity and clinical presentation of the condition.

Risk Factors

• Family history of fatty-acid oxidation disorders.
• Consanguineous relationships (parents who are closely related).
• Certain ethnic populations with higher carrier rates for specific mutations.

Symptoms

• Muscle weakness or pain, especially during exercise or fasting.
• Hypoglycemia (low blood sugar) or lethargy.
• Enlarged liver (hepatomegaly) or liver dysfunction.
• Neurological symptoms, such as seizures or developmental delays.
• Episodes of vomiting or poor feeding in infants.

Diagnosis

Diagnosis typically involves clinical evaluation, biochemical testing (e.g., blood or urine analysis for abnormal metabolites), and genetic testing to confirm the presence of specific mutations. Newborn screening may detect the condition in asymptomatic infants. Additional tests, such as enzyme activity assays or imaging, may be used to assess organ involvement.

Treatment Options

Treatment focuses on preventing metabolic crises by avoiding prolonged fasting and providing dietary management, including frequent meals and avoiding high-fat intake. During acute episodes, intravenous glucose and supportive care may be necessary. Long-term management may involve specialized dietary plans and monitoring by a metabolic specialist.

Prognosis and Follow-Up

With early diagnosis and proper management, many individuals can lead healthy lives. Regular follow-up with a metabolic specialist is essential to monitor growth, development, and metabolic stability. Prognosis depends on the severity of the condition and adherence to treatment plans.

Complications

Untreated or poorly managed cases may lead to severe complications, including hypoglycemic coma, liver failure, muscle damage, or neurological impairment. Acute metabolic crises can be life-threatening if not promptly addressed.

Lifestyle & Prevention

• Maintain a regular eating schedule to avoid prolonged fasting.
• Follow a diet low in medium-chain fats as recommended by a healthcare provider.
• Carry emergency medical information or supplies (e.g., glucose gel) for acute episodes.
• Educate family members and caregivers about the condition and emergency protocols.

When to Seek Professional Help

Seek immediate medical attention if symptoms of hypoglycemia (e.g., confusion, seizures, extreme lethargy) or metabolic crisis occur. Regular check-ups with a metabolic specialist are recommended to monitor the condition and adjust treatment as needed.

Tips for Medical Coders

When coding for medium chain acyl CoA dehydrogenase deficiency, use ICD-10-CM code E71.311. Ensure documentation supports the diagnosis, including clinical findings, diagnostic test results, and any genetic confirmation. Note any associated complications or management plans, as these may impact coding specificity. Avoid using this code for other fatty-acid oxidation disorders or unspecified conditions.